Medindia

X

GE Healthcare and Boston Scientific Collaborate on Cardiovascular Imaging

Monday, October 13, 2008 General News J E 4
Advertisement
WAUKESHA, Wis. and NATICK, Mass., Oct. 13 GEHealthcare (NYSE: GE) and intravascular ultrasound (IVUS) market leader BostonScientific Corporation (NYSE: BSX) today announced a collaboration thatenables improved intravascular ultrasound (IVUS) workflow between the GEHealthcare Innova(R) Cardiovascular X-ray System and the Boston ScientificiLab(R) Ultrasound Imaging System. The iLab and Innova Systems will both befeatured at the October 12-17 Transcatheter Cardiovascular Therapeutics (TCT)Scientific Symposium in Washington, D.C.

The Innova(R) System is the world's most trusted family of all-digitalcardiovascular imaging systems. The Innova X-ray imaging systems provide userswith excellent image quality with industry leading dose efficiency. Built onGE's industry leading Innova digital detector, the Innova System helpsphysicians clearly visualize fine vessels, precisely place stents andsuccessfully perform critical procedures. Cardiologists in the cardiac cathlab use it when performing procedures to view and treat potential coronaryartery blockages that could cause heart attacks or other seriouscardiovascular damage. The system is designed to provide cardiologists withmore information than ever before, resulting in better diagnosis and treatmentof cardiovascular disease.

"Instilling greater clinical confidence by delivering high performance,reliability and value to our customers is at the core of everything we do,"said Jayant Saha, General Manager, Interventional Global Marketing for GEHealthcare. "IVUS has proved to be an important and indispensable diagnostictool in interventional cardiology. Boston Scientific, a leading IVUS solutionsprovider, and GE look forward to offering the technological advances in thefield of IVUS to our joint customers and the patients they care for."

The Boston Scientific iLab(R) Ultrasound Imaging System can be directlyinstalled into the cardiac catheterization lab or radiology suite alongsidethe GE Innova X-ray System, enabling physicians to more readily incorporateIVUS technology into their procedures. With IVUS, a tiny catheter is insertedinto the heart or into a vessel where high-frequency sound waves reflect offtissue or vessel walls. The reflected sound waves create a cross-sectionalimage from within the vessel or heart to aid in visualizing vessel and heartstructure. IVUS is an important tool in determining treatment options becauseit is designed to offer a more complete picture from inside the artery orvessel and helps to optimize stent outcomes.

"Our cath lab has been a GE and Boston Scientific customer for over eightyears. We recently installed an iLab system alongside our GE cath lab and havefound that the use of both technologies has improved the ease of use inperforming IVUS," said Francis Boucek, M.D., of Naples Community Hospital, FL.

"Any time two leadership companies like GE Healthcare and BostonScientific pair together to offer workflow improvements, the patientbenefits," said Hank Kucheman, Senior Vice President and Group President ofBoston Scientific's Cardiovascular business. "The best technologies in thecardiovascular imaging business just got better and with our continuedcollaboration, GE Healthcare and Boston Scientific will bring best-in-classpatient care to physicians around the world."

About GE Healthcare

GE Healthcare provides transformational medical technologies and servicesthat are shaping a new age of patient care. Our expertise in medical imagingand information technologies, medical diagnostics, patient monitoring systems,performance improvement, drug discovery, and biopharmaceutical manufacturingtechnologies is helping clinicians around the world re-imagine new ways topredict, diagnose, inform, treat and monitor disease, so patients can livetheir lives to the fullest.

GE Healthcare's broad range of products and services enable healthcareproviders to better diagnose and treat cancer, heart disease, neurologicaldiseases and other conditions earlier. Our vision for the future is to enablea new "early health" model of care focused on earlier diagnosis,pre-symptomatic disease detection and disease prevention. Headquartered in theUnited Kingdom, GE Healthcare is a $17 billion unit of General ElectricCompany (NYSE: GE). Worldwide, GE Healthcare employs more than 46,000 peoplecommitted to serving healthcare professionals and their patients in more than100 countries. For more information about GE Healthcare, visit our website athttp://www.gehealthcare.com.

About Boston Scientific

Boston Scientific is a worldwide developer, manufacturer and marketer ofmedical devices whose products are used in a broad range of interventionalmedical specialties. For more information, please visit:http://www.bostonscientific.com.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaningof Section 21E of the Securities Exchange Act of 1934. Forward-lookingstatements may be identified by words like "anticipate," "expect," "project,""believe," "plan," "estimate," "intend" and similar words. Theseforward-looking statements are based on our beliefs, assumptions and estimatesusing information available to us at the time and are not intended to beguarantees of future events or performance. These forward-looking statementsinclude, among other things, statements regarding our product performance,significance of event data, and our growth strategy. If our underlyingassumptions turn out to be incorrect, or if certain risks or uncertaintiesmaterialize, actual results could vary materially from the expectations andprojections expressed or implied by our forward-looking statements. Thesefactors, in some cases, have affected and in the future (together with otherfactors) could affect our ability to implement our business strategy and maycause actual results to differ materially from those contemplated by thestatements expressed in this press release. As a result, readers are cautionednot to place undue reliance on any of our forward-looking statements.

Factors that may cause such differences include, among other things:future economic, competitive, reimbursement and regulatory conditions; newproduct introductions; demographic trends; intellectual property; litigation;financial market conditions; and, future business decisions made by us and ourcompetitors. All of these factors are difficult or impossible to predictaccurately and many of them are beyond our control. For a further list anddescription of these and other important risks and uncertainties that mayaffect our future operations, see Part I, Item 1A - Risk Factors in our mostrecent Annual Report on Form 10-K filed with the Securities and ExchangeCommission, which we may update in Part II, Item 1A - Risk Factors inQuarterly Reports on Form 10-Q we have filed or will file thereafter. Wedisclaim any intention or obligation to publicly update or revise anyforward-looking statements to reflect any change in our expectations or inevents, conditions, or circumstances on which those expectations may be based,or that may affect the likelihood that actual results will differ from thosecontained in the forward-looking statements. This cautionary statement isapplicable to all forward-looking statements contained in this document.Contact for GE Healthcare: Corey Miller 414-469-5499 (mobile) Media Relations GE Healthcare Contacts for Boston Scientific: Paul Donovan 508-650-8541 (office) 508-667-5165 (mobile) Media Relations Boston Scientific Corporation Larry Neumann 508-650-8696 (office) Investor Relations Boston Scientific Corporation

SOURCE Boston Scientific Corporation
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
USGI Announces Key Management Appointments
S
PharmAthene and Panacea Biotec Ltd. Establish Stra...